NeoPro Labs (NPL) was established in 2002 and its goal is to develop its proprietary technology to enhance crop resistance to pathogens and other environmental stress.

NPL owns a unique intellectual property portfolio that covers its peptide library and allows the company to differentiate itself from its competitors. The intellectual property portfolio contains methods of using and screening of the peptide library, and composition-of-matter for the peptide library and individuals. These patents are not minor changes in existing drugs. They are fundamental patents on a novel mechanism of action. The patents will expire in 2025, with possible extensions until 2030. It will allow commercialization of the technology in the US and the world with limited competition for the next decade.